Seven ADR reports of gangrene and/or peripheral cyanosis associated with the use of norepinephrine [noradrenaline; Cardi
- PDF / 136,168 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 61 Downloads / 139 Views
1
■ Seven ADR reports of gangrene and/or peripheral cyanosis associated with the use of norepinephrine [noradrenaline; Cardiamed] have been received by the Malaysian National Pharmaceutical Control Bureau. The patients developed gangrene on their toes, fingers and legs and/or peripheral cyanosis 2 to 5 days after the injection. All patients received the recommended norepinephrine dose of 0.13 to 0.3 µg/kg/min diluted in 5% dextrose saline, infused through a dedicated central line. Following discussions, the manufacturer of Cardiamed voluntarily recalled Cardiamed batches from the market due to potential patient safety concerns. Ministry of Health Malaysia. Cardiamed (Rm) (noradrenaline) injection. 801052663 Malaysian Adverse Drug Reactions Newsletter : 11, May 2008
0114-9954/10/1211-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 19 Jul 2008 No. 1211
Data Loading...
